Literature DB >> 27041564

The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action.

A Griveau1,2,3,4, G Devailly1,2,3,4, L Eberst1,2,3,4, N Navaratnam5, B Le Calvé1,2,3,4, M Ferrand1,2,3,4, P Faull6, A Augert1,2,3,4, R Dante1,2,3,4, J M Vanacker7, D Vindrieux1,2,3,4, D Bernard1,2,3,4.   

Abstract

Little is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein. In recent years, PLA2R1 has been shown to have an important role in regulating tumor-suppressive responses via JAK2 activation, but the underlying mechanisms are largely undeciphered. In this study, we observed that PLA2R1 increases the mitochondrial content, judged by increased levels of numerous mitochondrial proteins, of the mitochondrial structural component cardiolipin, of the mitochondrial DNA content, and of the mitochondrial DNA replication and transcription factor TFAM. This effect of PLA2R1 relies on a transcriptional program controlled by the estrogen-related receptor alpha1 (ERRα) mitochondrial master regulator. Expression of ERRα and of its nucleus-encoded mitochondrial targets is upregulated upon PLA2R1 ectopic expression, and this effect is mediated by JAK2. Conversely, downregulation of PLA2R1 decreases the level of ERRα and of its nucleus-encoded mitochondrial targets. Finally, blocking the ERRα-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERRα and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27041564     DOI: 10.1038/onc.2016.43

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  A family of cytokine-inducible inhibitors of signalling.

Authors:  R Starr; T A Willson; E M Viney; L J Murray; J R Rayner; B J Jenkins; T J Gonda; W S Alexander; D Metcalf; N A Nicola; D J Hilton
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

2.  Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin.

Authors:  Anaïs Fradet; Helène Sorel; Lamia Bouazza; Delphine Goehrig; Baptiste Dépalle; Akeila Bellahcène; Vincent Castronovo; Hélène Follet; Françoise Descotes; Jane E Aubin; Philippe Clézardin; Edith Bonnelye
Journal:  Cancer Res       Date:  2011-07-06       Impact factor: 12.701

Review 3.  Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond.

Authors:  Geneviève Deblois; Vincent Giguère
Journal:  Nat Rev Cancer       Date:  2012-11-29       Impact factor: 60.716

4.  Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis.

Authors:  Geneviève Deblois; Ghada Chahrour; Marie-Claude Perry; Guillaume Sylvain-Drolet; William J Muller; Vincent Giguère
Journal:  Cancer Res       Date:  2010-10-20       Impact factor: 12.701

Review 5.  The role of Stat5 transcription factors as tumor suppressors or oncogenes.

Authors:  G Ferbeyre; R Moriggl
Journal:  Biochim Biophys Acta       Date:  2010-10-20

6.  ERRα augments HIF-1 signalling by directly interacting with HIF-1α in normoxic and hypoxic prostate cancer cells.

Authors:  Chang Zou; Shan Yu; Zhenyu Xu; Dinglan Wu; Chi-Fai Ng; Xiaoqiang Yao; David T Yew; Jean-Marc Vanacker; Franky L Chan
Journal:  J Pathol       Date:  2014-02-05       Impact factor: 7.996

7.  Estrogen-related receptor α decreases RHOA stability to induce orientated cell migration.

Authors:  Juliette Sailland; Violaine Tribollet; Christelle Forcet; Cyrielle Billon; Bruno Barenton; Julie Carnesecchi; Alice Bachmann; Karine Cécile Gauthier; Shan Yu; Vincent Giguère; Franky L Chan; Jean-Marc Vanacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

8.  Nuclear receptor ERR alpha and coactivator PGC-1 beta are effectors of IFN-gamma-induced host defense.

Authors:  Junichiro Sonoda; Josée Laganière; Isaac R Mehl; Grant D Barish; Ling-Wa Chong; Xiangli Li; Immo E Scheffler; Dennis C Mock; Alain R Bataille; Francois Robert; Chih-Hao Lee; Vincent Giguère; Ronald M Evans
Journal:  Genes Dev       Date:  2007-08-01       Impact factor: 11.361

9.  Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells.

Authors:  Mario Menschikowski; Uwe Platzbecker; Albert Hagelgans; Margot Vogel; Christian Thiede; Claudia Schönefeldt; Renate Lehnert; Graeme Eisenhofer; Gabriele Siegert
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

10.  Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice.

Authors:  Satomi Miwa; Howsun Jow; Karen Baty; Amy Johnson; Rafal Czapiewski; Gabriele Saretzki; Achim Treumann; Thomas von Zglinicki
Journal:  Nat Commun       Date:  2014-05-12       Impact factor: 14.919

View more
  10 in total

Review 1.  Estrogen-related receptor alpha in select host functions and cancer: new frontiers.

Authors:  Harmit S Ranhotra
Journal:  Mol Cell Biochem       Date:  2022-02-09       Impact factor: 3.396

Review 2.  Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson-Gilford progeria syndrome.

Authors:  Saurabh Saxena; Sanjeev Kumar
Journal:  Geroscience       Date:  2020-02-11       Impact factor: 7.713

3.  Diverse effects of phospholipase A2 receptor expression on LNCaP and PC-3 prostate cancer cell growth in vitro and in vivo.

Authors:  Markus Friedemann; Brit Nacke; Albert Hagelgans; Carsten Jandeck; Nicole Bechmann; Martin Ullrich; Birgit Belter; Christin Neuber; Olga Sukocheva; Jens Pietzsch; Mario Menschikowski
Journal:  Oncotarget       Date:  2018-11-13

4.  Targeting the phospholipase A2 receptor ameliorates premature aging phenotypes.

Authors:  Audrey Griveau; Clotilde Wiel; Benjamin Le Calvé; Dorian V Ziegler; Sophia Djebali; Marine Warnier; Nadine Martin; Jacqueline Marvel; David Vindrieux; Martin O Bergo; David Bernard
Journal:  Aging Cell       Date:  2018-09-14       Impact factor: 9.304

5.  PLA2R1 promotes DNA damage and inhibits spontaneous tumor formation during aging.

Authors:  Anda Huna; Audrey Griveau; David Vindrieux; Sara Jaber; Jean-Michel Flaman; Delphine Goehrig; Lamia Azzi; Jean-Jacques Médard; Sophia Djebali; Hector Hernandez-Vargas; Robert Dante; Léa Payen; Jacqueline Marvel; Philippe Bertolino; Sébastien Aubert; Pierre Dubus; David Bernard
Journal:  Cell Death Dis       Date:  2021-02-16       Impact factor: 8.469

6.  Treatment of Mouse Sperm with a Non-Catalytic Mutant of PLA2G10 Reveals That PLA2G10 Improves In Vitro Fertilization through Both Its Enzymatic Activity and as Ligand of PLA2R1.

Authors:  Roland Abi Nahed; Magali Dhellemmes; Christine Payré; Emilie Le Blévec; Jean-Philippe Perrier; Sylviane Hennebicq; Jessica Escoffier; Pierre F Ray; Corinne Loeuillet; Gérard Lambeau; Christophe Arnoult
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

7.  Comprehensive analysis of tissue proteomics in patients with papillary thyroid microcarcinoma uncovers the underlying mechanism of lymph node metastasis and its significant sex disparities.

Authors:  Zhen Cao; Zejian Zhang; Xiaoyue Tang; Rui Liu; Mengwei Wu; Jianqiang Wu; Ziwen Liu
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

8.  The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes.

Authors:  Audrey Griveau; Clotilde Wiel; Dorian V Ziegler; Martin O Bergo; David Bernard
Journal:  Aging Cell       Date:  2020-03-20       Impact factor: 9.304

9.  Clinical Significance of Expression Changes and Promoter Methylation of PLA2R1 in Tissues of Breast Cancer Patients.

Authors:  Noha Mitwally; Einas Yousef; Ahmad Abd Al Aziz; Mohamed Taha
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

10.  Anti-phospholipase A2 receptor antibodies directly induced podocyte damage in vitro.

Authors:  Yanfen Li; Juntao Yu; Miao Wang; Zhao Cui; Ming-Hui Zhao
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.